Women produce testosterone, and it is not a trace curiosity. It is present throughout adult life and involved in sexual desire, mood, muscle and bone. Where the female literature differs from the male is not in whether the hormone matters — it is in how much has been studied, and how much of that study has produced usable clinical guidance.
The most authoritative statement is a Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published in 2019 and endorsed across the major endocrine and menopause societies.[1] That such a statement was needed in 2019 says something about how long the field went without one.
What the consensus establishes
The 2019 global position statement is the reference point for what testosterone therapy in women is and is not supported for.[1] Its existence is the achievement: a single agreed position, arrived at internationally, in a field that had previously been governed by extrapolation from male data and local practice.
Alongside it sits the systematic review and meta-analysis of randomised controlled trial data on the safety and efficacy of testosterone for women, published in The Lancet Diabetes & Endocrinology the same year.[2] Those two papers are the evidentiary spine of the subject.
Why the dosing question is not a scaling question
The intuitive assumption — that female dosing is male dosing divided down — is wrong in a way that matters.
Women's physiological testosterone concentrations are a small fraction of men's, which means the margin between a physiological female dose and an inadvertently supraphysiological one is narrow. Precision matters more, not less, and formulations designed for men are not straightforwardly divisible.
That is why the global consensus statement exists as a separate document rather than as an appendix to the male guideline.[1] The subject is covered in dosing women differently.
Why this season sits in The T Files
A note on where you are. This is season 7 of a serialised history of testosterone, which lives under men's testosterone in this hub's structure. These episodes are about women's testosterone; they are not the clinical resource for women.
That resource is testosterone therapy for women, written from the primary literature under the women's pillar. If you are a woman looking for clinical information rather than the history, start there.
Frequently asked questions
How much testosterone do women have? Substantially less than men, and it varies across the lifespan. Interpretation belongs with a clinician using assays validated for the female range — a real constraint, since many assays were built for male concentrations.
Is testosterone therapy approved for women? The global consensus position statement sets out the international position.[1] Regulatory approval status varies by country and by indication.
Does testosterone drop at menopause? The trajectory of androgens across the menopause transition differs from that of estrogen, and is one of the areas the consensus statement addresses.[1]
Next in this series
If women make testosterone and it does real work, the obvious question is what happens when there is not enough.
Continue with what low testosterone actually does to women.
References
3 sources
- Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660–4666. doi:10.1210/jc.2019-01603 · PMID 31498871
- Islam RM, Bell RJ, Green S, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754–766. doi:10.1016/S2213-8587(19)30189-5 · PMID 31353194
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107–117. doi:10.1056/NEJMoa2215025 · PMID 37326322
Practical questions about membership, labs and using the spray are answered in the Learn Hub FAQ.